-

11:15:07 PM

LNTH Stock News

LNTH - Lantheus Holdings Inc

09/13/21 8:00 AM

Nasdaq : LNTH

Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network® (NCCN) Guidelines for Prostate Cancer

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an

RHEA-AI

positive

09/13/21 7:30 AM

Nasdaq : LNTH

Lantheus and RefleXion Announce Development and Commercialization Collaboration with the Potential to Improve Future Prostate Cancer Treatment

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) and RefleXion Medical, Inc., today announced a development and commercialization collaboration to evaluate the use of piflufolastat F 18, Lantheus’ prostate-specific

RHEA-AI

very positive

09/10/21 8:30 AM

Nasdaq : LNTH

Lantheus Announces Presentation at the 2021 American Urological Association (AUA) Annual Meeting

Highlights Piflufolastat F 18’s Potential to Change Initial Risk Assessment and Intended Patient Management in High-Risk Prostate Cancer Identified Regional Lymph Node and/or Distant Metastases in 26.9% of Patients Prior to Definitive Therapy NORTH BILLERICA, Mass., Sept. 10, 2021 (GLOBE

RHEA-AI

neutral

09/02/21 8:00 AM

Nasdaq : LNTH

conferences

Lantheus Holdings to Present at Upcoming Investor Conferences

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow

RHEA-AI

neutral

07/29/21 6:25 PM

Nasdaq : LNTH

Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lantheus’ Leadership in Prostate Cancer

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced today that its subsidiary, EXINI Diagnostics AB, was granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its digital application, aPROMISE™ ( a utomated PRO state Cancer M olecular I maging S tandardized E

RHEA-AI

very positive

07/28/21 7:00 AM

Nasdaq : LNTH

earnings

Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today reported financial results for its second

RHEA-AI

neutral

07/14/21 8:00 AM

Nasdaq : LNTH

conferencesearnings

Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call and Webcast on July 28, 2021 at 8:00 a.m. Eastern Time

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 28, 2021, to discuss its financial and operating results for the second quarter of 2021.To access the live conference call via telephone,

RHEA-AI

neutral

06/14/21 8:30 AM

Nasdaq : LNTH

conferences

Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced that data from the

RHEA-AI

neutral

05/27/21 7:00 AM

Nasdaq : LNTH

fda approval

Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today that the U.S. Food and

RHEA-AI

neutral

05/21/21 8:30 AM

Nasdaq : LNTH

Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today a poster presentation

RHEA-AI

neutral

Prev 1 2 3 4 5 6 7 Next

LNTH Data

Websiteinvestor.lantheus.com
CeoMary Heino
Security nameLantheus Holdings Inc
Issue typecs
Sic code2835
Employees595
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Surgical and Medical Instrument Manufacturing
Address331 Treble Cove Rd
StateMassachusetts
CityNorth Billerica
Zip01862-2849
CountryUS
Phone19786718001

About Lantheus Holdings Inc

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow™ serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden.